The combined global market size of medical conditions we target exceeds US$400B per annum. This potential addressable market is calculated by combining the treatment markets of OSA, TBI, concussion, rheumatoid arthritis, inflammatory bowel disease, inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis) and generalised anxiety disorder (GAD). Success in the clinical development programmes will not only provide benefit to patients, but also offer significant economic potential for our shareholders.
Introducing The Clarion Clinics Group
Psychennex is pioneering the worldʼs leading Psychedelic-Assisted Psychotherapy Clinics.
Introducing The Clarion Clinics Group
Psychennex is pioneering the worldʼs leading Psychedelic-Assisted Psychotherapy Clinics.
The Potential is Limitless
Incannex is a global leader in the development of novel, medicinal cannabinoid compounds and psychedelic therapies.
The Potential is Limitless
Incannex is a global leader in the development of novel, medicinal cannabinoid compounds and psychedelic therapies.
Boundless Medical Developments
Undertaking 28 clinical programs, targeting conditions for which there are no current pharmacotherapy treatments.
Boundless Medical Developments
Undertaking 28 clinical programs, targeting conditions for which there are no current pharmacotherapy treatments.
Unrivalled Economic Opportunities
The addressable global market size of the indications we are targeting is over US$400 billion.
Unrivalled Economic Opportunities
The addressable global market size of the indications we are targeting is over US$400 billion.
Our mission is to alleviate human suffering by creating novel, ethical drugs and therapies for patients with unmet medical needs, utilising compounds and delivery systems with strong pre-existing scientific signals of efficacy.
28 R&D programs and 6 clinical trials, with 1 primary goal – alleviate human suffering.


Clinical Development Pathway
Incannex is a medicinal cannabinoid and psychedelic therapy development company undertaking phase 2 clinical trials guided by its extended team, post liaison with FDA. With a diverse portfolio of 28 distinct research and development programs, 6 clinical trials underway and more planned, our programs target conditions for patients with unmet medical needs. This means we have an opportunity to treat a significant number of people – the potential is limitless.
US$400B market potential.


Latest results and presentations
FDA application prepared: Psilocybin-assisted psychotherapy program
Health & Biotech Incannex Healthcare (ASX: IHL) subsidiary Psychennex Pty Ltd has started preparing an investigational new drug (IND)...FDA clearance to start IHL-42X clinical trial with OSA patients
Health & Biotech Incannex Healthcare (ASX: IHL) has received approval from the US Food and Drug Administration (FDA) to...Clarion Clinics ready to open
Health & Biotech Incannex Healthcare’s (ASX: IHL) subsidiary, Clarion Clinics Group, has begun accepting registrations of interest from...Positive pre-IND meeting for IHL-675A arthritis treatment
Health & Biotech Chief scientific officer Dr Mark Bleackley tells Proactive about its positive pre-IND meeting for IHL-675A...Key application submitted to FDA for $15bn sleep apnoea market
Health & Biotech Key application submitted to FDA for new treatment in $15 billion sleep apnoea market...Ethics approval: Phase 2 clinical trial – rheumatoid arthritis
Health & Biotech Incannex has been given the green light to start its Phase 2 clinical trial to...IHL-42X (OSA) bioequivalence/bioavailability ethic approval
Health & Biotech Incannex has received approval from Bellberry Human Research Ethic Committee ('HREC') to commence the bioequivalence/bioavailability...Lead investigators appointed for clinical trial into sleep apnoea
Health & Biotech Special Report: Incannex Healthcare has recruited two highly experienced lead principal investigators (PIs) for the...World renowned psychedelic experts join Clarion Clinic’s board
Health & Biotech Special Report: Incannex Healthcare has announced that three of the world’s top psychedelic therapy and science...90 Seconds With Peter Widdows
Health & Biotech Got 90 seconds? Then listen to Director, Peter Widdows tell us about their company news....Psychennex to open psychedelic clinics and capture opportunity
Health & Biotech Special Report: Incannex’s psychedelics focused subsidiary, Psychennex, believes that it has the best team of...Australia’s first psychedelic-assisted psychotherapy clinic
Health & Biotech Special Report: Incannex Healthcare’s subsidiary Clarion Clinics will be the first dedicated psychedelic-assisted psychotherapy business...Anti-inflammatory drug (IHL-675A) well tolerated in Phase-1 trial
Health & Biotech Special Report: Results from a Phase-1 clinical of Incannex’s anti-inflammatory drug IHL-675A in healthy volunteers...Incannex fast tracks products for addiction and skin diseases
Health & Biotech Special Report: Incannex has made a key appointment as it works to advance its CannQuit-N...Incannex to open psychotherapy clinic with leading experts
Health & Biotech Special Report: IHL is undergoing a pivotal point in its journey as a company moving...Notable benefit for psilocybin over placebo when treating anxiety
Health & Biotech Special Report: Even though specific data from the PsiGAD trial cannot yet be released until...Commencing manufacture of psilocybin for commercial applications
Health & Biotech Special Report: As Australia becomes the first country to recognise psychedelics as medicine, Incannex Healthcare...Psilocybin locked-in for trials and potential commercialisation
Health & Biotech Incannex has reached another milestone in progressing its psilocybin drug product by engaging Catalent to...Incannex kicks off Phase 2 rheumatoid arthritis trial
Health & Biotech Incannex CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial,...Phase 2 trial commences for treatment of rheumatoid arthritis
Health & Biotech Incannex commences phase 2 trial assessing IHL-675A for treatment of rheumatoid arthritis....TGA allows psilocybin and MDMA for treating depression and PTSD
Health & Biotech Australia leads the way as TGA allows psilocybin and MDMA for treating depression and PTSD....Incannex at forefront of psychedelic research and development
Health & Biotech Independent analysis has started of Incannex’s Phase 2 clinical trial to assess its psilocybin-assisted psychotherapy...CEO Joel Latham speaks with Proactive after raising A$13 million
Health & Biotech Watch Incannex CEO Joel Latham speak with Proactive after raising A$13 million in a placement...Incannex files patent to expand IHL-42X intellectual property
Health & Biotech Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has filed a provisional patent application for additional protection of...Eurofins to manufacture Incannex’s topical cannabinoid formulation to treat common skin conditions
Health & Biotech Clinical stage pharmaceutical cannabinoid and psychedelics company Incannex has engaged Eurofins to manufacture ReneCann Therapeutic Topical...Incannex appoints Eurofins to manufacture novel addiction treatments CannQuit-N and CannQuit-O
Health & Biotech Incannex is teaming with Eurofins to help people with opioid and nicotine addiction disorders, by...Incannex completes US FDA meeting for IHL-216A in treating traumatic brain injury
Health & Biotech Incannex Healthcare completes US FDA meeting for IHL-216A in treating traumatic brain injury. The US...Incannex initiates big clinical trial and details FDA plans for pivotal clinical trials for sleep apnoea drug
Health & Biotech Special Report: Incannex Healthcare commits to a 116-person bioavailability/ bioequivalence (BA/BE) study and will submit...Subscribe
Stay up to date with Incannex’s research and development program.